In conversation with... Steven Horwitz

from Listen to The Lancet Oncology · host The Lancet

Dr Steven Horwitz (Memorial Sloan Kettering Cancer Center, New York, NY, USA) discusses a phase 1 study of valemetostat in relapsed or refractory non-Hodgkin lymphoma and a phase 2 study of valemetostat in relapsed or refractory peripheral T-cell lymphoma.

Episode metadata supplied by the publisher feed · Published Oct 30, 2024

Embed this episode

Attribution link and audio player

NOW PLAYING

In conversation with... Steven Horwitz

0:00 15:07

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Listen to The Lancet Oncology?

This episode is 15 minutes long.

When was this Listen to The Lancet Oncology episode published?

This episode was published on October 30, 2024.

Can I download this Listen to The Lancet Oncology episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!